Efficacy of Adjunct Olanzapine Treatment in Adolescents With Anorexia Nervosa: A Comparison of Two Patient Cohorts
European Eating Disorders Review · 2025
DOI: 10.1002/erv.70009 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Eating Disorders Review, 2025. Verfasst von Helene Krauss und 10 weiteren Autor:innen. Beteiligte Einrichtung: Eating Disorders Unit, Department of Child and Adolescent Psychiatry, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Anorexia Nervosa, Antipsychotic Agents, Weight Gain, Benzodiazepines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bundesinstitut für Arzneimittel und Medizinprodukte, German Federal Ministry of Education and Research.
Abstract (Originalsprache)
Background
Anorexia nervosa (AN) is a severe psychiatric disorder with high mortality, requiring innovative treatment strategies. Olanzapine (OLZ), an atypical antipsychotic, has demonstrated efficacy in promoting weight gain and reducing psychopathological symptoms in adults with AN. However, its efficacy and safety in adolescents remain insufficiently explored.
Objective
This study assessed the impact of adjunctive OLZ in adolescents with AN during inpatient care, focussing on weight gain, eating disorder pathology, and metabolic safety.
Methods
A naturalistic, prospective study compared two groups of adolescent inpatients with AN ( n = 47 each), one receiving standard multidisciplinary care plus OLZ and one receiving standard care alone (Non‐OLZ). Weekly weight gain as well as admission‐to‐discharge changes in body‐mass‐index, eating disorder symptoms, and metabolic markers were compared between the two cohorts.
Results
The OLZ group (∅ 9 mg/day) achieved greater weekly weight gain (0.898 vs. 0.677 kg, p = 0.004) compared to the Non‐OLZ group. Both groups showed similar reductions in eating disorder pathology; however, improvements in body dissatisfaction were larger in the Non‐OLZ group. Administration of OLZ was associated with significant prolactin level increases.
Conclusions
OLZ is a promising adjunctive treatment for adolescents in terms of supporting weight gain during inpatient care. However, psychological effects and possible metabolic risks warrant further study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eating Disorders Unit, Department of Child and Adolescent Psychiatry, Medical University of Vienna, Vienna, Austria.
- Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Centre for Mental Health, University Hospital of Wuerzburg, Wuerzburg, Germany.
ORCID-Profile: Helene Krauss, Michael Zeiler, Julia Klang, Gudrun Wagner, Karin Egberts, Andreas Karwautz
Förderung
- Bundesinstitut für Arzneimittel und Medizinprodukte
- German Federal Ministry of Education and Research
Zitieren
APA
Krauss, H., Zeiler, M., Mairhofer, D., Klang, J., Schwarzenberg, J., Mitterer, M., Wagner, G., Glüder, M., Egberts, K., Gerlach, M., & Karwautz, A. (2025). Efficacy of Adjunct Olanzapine Treatment in Adolescents With Anorexia Nervosa: A Comparison of Two Patient Cohorts. European Eating Disorders Review. https://doi.org/10.1002/erv.70009
Vancouver
Krauss H, Zeiler M, Mairhofer D, Klang J, Schwarzenberg J, Mitterer M, et al. Efficacy of Adjunct Olanzapine Treatment in Adolescents With Anorexia Nervosa: A Comparison of Two Patient Cohorts. European Eating Disorders Review. 2025. doi:10.1002/erv.70009
BibTeX
@article{Krauss2025,
author = {Krauss, Helene and Zeiler, Michael and Mairhofer, Dunja and Klang, Julia and Schwarzenberg, Julia and Mitterer, Michaela and Wagner, Gudrun and Glüder, Maria and Egberts, Karin and Gerlach, Manfred and Karwautz, Andreas},
title = {Efficacy of Adjunct Olanzapine Treatment in Adolescents With Anorexia Nervosa: A Comparison of Two Patient Cohorts},
journal = {European Eating Disorders Review},
year = {2025},
doi = {10.1002/erv.70009}
}
EUVIMED